A Study of Thymopentin Effects on HIV-1 Infectivity of Blood Mononuclear Cells and Semen in HIV Infected Patients

Launched by IMMUNOBIOLOGY RESEARCH INSTITUTE · Aug 30, 2001

Keywords

ClinConnect Summary

No description provided

Gender

ALL

Eligibility criteria

• • Inclusion Criteria
• Concurrent Medication:
• Allowed:
• • Aerosolized pentamidine.
• Patients must have the following:
• • Seropositive for HIV-1 (ELISA assay) confirmed by Western blot.
• • HIV-1 p24 antigen must be detected in supernatant fluids from co-cultures of patients' PBMC on two separate occasions.
• • Voluntarily sign consent.
• • Patients with HIV "wasting syndrome" are allowed.
• Prior Medication:
• Allowed:
• • Aerosolized pentamidine.
• • Exclusion Criteria
• Co-existing Condition:
• Patients with the following are excluded:
• • AIDS as defined by the CDC.
• • Significant hepatic disease.
• • Thrombocytopenia.
• • Hypersensitivity to thymopentin.
• • Hemophilia A or B or other hematologic disorders requiring current or previous administration of blood products.
• • Abnormal chest x-ray (indicative of active disease (opportunistic infection)) within 30 days prior to study entry.
• Patients with the following are excluded:
• • AIDS as defined by the CDC.
• • Significant hepatic disease.
• • Thrombocytopenia.
• • Hypersensitivity to thymopentin.
• • Hemophilia A or B or other hematologic disorders requiring current or previous administration of blood products.
• • Abnormal chest x-ray (indicative of active disease (opportunistic infection)) within 30 days prior to study entry.
• Prior Medication:
• Excluded within 30 days of study entry:
• • Immunomodulatory or experimental therapy.
• * Excluded within 90 days of study entry:
• • Zidovudine (AZT).
• • Intravenous drug abuse.